- Home
- PSNL vs XERS Comparison
PSNL vs XERS Comparison
Compare PSNL & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSNL
- XERS
- Stock Information
- Founded
- PSNL 2011
- XERS 2005
- Country
- PSNL United States
- XERS United States
- Employees
- PSNL N/A
- XERS N/A
- Industry
- PSNL Medical Specialities
- XERS Biotechnology: Pharmaceutical Preparations
- Sector
- PSNL Health Care
- XERS Health Care
- Exchange
- PSNL Nasdaq
- XERS Nasdaq
- Market Cap
- PSNL 460.7M
- XERS 500.2M
- IPO Year
- PSNL 2019
- XERS 2018
- Fundamental
- Price
- PSNL $4.89
- XERS $3.20
- Analyst Decision
- PSNL Strong Buy
- XERS Buy
- Analyst Count
- PSNL 4
- XERS 3
- Target Price
- PSNL $8.56
- XERS $4.87
- AVG Volume (30 Days)
- PSNL 1.5M
- XERS 1.4M
- Earning Date
- PSNL 02-26-2025
- XERS 03-05-2025
- Dividend Yield
- PSNL N/A
- XERS N/A
- EPS Growth
- PSNL N/A
- XERS N/A
- EPS
- PSNL N/A
- XERS N/A
- Revenue
- PSNL $87,489,000.00
- XERS $187,361,000.00
- Revenue This Year
- PSNL $15.76
- XERS $24.27
- Revenue Next Year
- PSNL $4.90
- XERS $18.57
- P/E Ratio
- PSNL N/A
- XERS N/A
- Revenue Growth
- PSNL 24.05
- XERS 22.72
- 52 Week Low
- PSNL $1.12
- XERS $1.69
- 52 Week High
- PSNL $7.20
- XERS $3.87
- Technical
- Relative Strength Index (RSI)
- PSNL 45.39
- XERS 41.99
- Support Level
- PSNL $5.22
- XERS $3.14
- Resistance Level
- PSNL $5.50
- XERS $3.60
- Average True Range (ATR)
- PSNL 0.57
- XERS 0.17
- MACD
- PSNL -0.18
- XERS -0.04
- Stochastic Oscillator
- PSNL 8.33
- XERS 11.32
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.